Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

VTGN holding history

Vistagen Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

VTGN overviewAll 13F holders of VTGNFull Q2 2026 holdings

Shares (Q2 2026)
57,830
Value
$13.1K
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of VTGN by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202657,830$13.1K<0.1%−20,906−26.6%ReducedHolders
Q1 202678,736$45.0K<0.1%+26,743+51.4%AddedHolders
Q4 202551,993$34.4K<0.1%+26,326+102.6%AddedHolders
Q3 202525,667$91.1K<0.1%+2,854+12.5%AddedHolders
Q2 202522,813$45.6K<0.1%−2,966−11.5%ReducedHolders
Q1 202525,779$64.4K<0.1%−106,535−80.5%ReducedHolders
Q4 2024132,314$390.3K<0.1%+122,193+1,207.3%AddedHolders
Q3 202410,121$30.5K<0.1%−9,145−47.5%ReducedHolders
Q2 202419,266$67.0K<0.1%+14,530+306.8%AddedHolders
Q1 20244,736$25.0K<0.1%+4,619+3,947.9%AddedHolders
Q4 2023117$601<0.1%−1,381−92.2%ReducedHolders
Q3 20231,498$7.85K<0.1%+1,381+1,180.3%AddedHolders
Q2 2023117$219<0.1%−6,459−98.2%ReducedConverted for a 1-for-30 splitHolders
Q1 2023197,268$24.7K<0.1%+14,622+8.0%AddedHolders
Q4 2022182,646$18.3K<0.1%+182,646NewHolders
Q3 20220$00.0%−23,461−100.0%Sold outHolders
Q2 202223,461$21.0K<0.1%+10,539+81.6%AddedHolders
Q1 202212,922$16.0K<0.1%−433,866−97.1%ReducedHolders
Q4 2021446,788$871.0K<0.1%+233,571+109.5%AddedHolders
Q3 2021213,217$585.0K<0.1%+212,967+85,186.8%AddedHolders
Q2 2021250$1.00K<0.1%−10,549−97.7%ReducedHolders
Q1 202110,799$23.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.